ReviewOncology letters2025
Role and mechanistic study of long non-coding RNA maternally expressed gene 3 in gastric cancer (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding (lnc)RNAs are notable participants in gene regulation, and maternally expressed gene 3 (MEG3) has been implicated in the development and progression of several types of cancer, underscoring its potential as a key player in oncogenesis. The present review aimed to explore the functional role of MEG3 in gastric cancer (GC) and elucidate the underlying molecular mechanisms, as well as to summarize the expression changes of MEG3 in GC, its influence on tumor cell biological behaviors and the potential signaling pathways involved. Ultimately, the present synthesis of current knowledge seeks to provide novel insights for the diagnosis and treatment of GC, highlighting MEG3 as a promising target for future therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.